Detalhe da pesquisa
1.
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Liver Int
; 44(6): 1343-1350, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38436529
2.
Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
Int J Clin Oncol
; 29(2): 188-194, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37991558
3.
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Oncologist
; 28(7): e526-e533, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37023703
4.
FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study.
BMC Cancer
; 23(1): 177, 2023 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809997
5.
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study.
Hepatol Res
; 53(5): 409-416, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601972
6.
Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
World J Surg Oncol
; 21(1): 263, 2023 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37620940
7.
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
BMC Cancer
; 22(1): 517, 2022 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35525913
8.
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Pancreatology
; 22(6): 789-796, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35705458
9.
Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer.
Nutr Cancer
; 74(1): 122-130, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438442
10.
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.
Hepatol Res
; 52(3): 269-280, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34761470
11.
Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma.
Langenbecks Arch Surg
; 407(4): 1525-1535, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35217927
12.
Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer.
Cancer Sci
; 112(11): 4679-4691, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382298
13.
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
Oncologist
; 26(2): 97-e201, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010112
14.
Association between time to stent dysfunction and the anti-tumour effect of systemic chemotherapy following stent placement in patients with pancreaticobiliary cancers and malignant gastric outlet obstruction: a retrospective cohort study.
BMC Cancer
; 21(1): 576, 2021 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011301
15.
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
Hepatol Res
; 51(2): 201-215, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270323
16.
Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
Digestion
; 102(4): 654-662, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32841939
17.
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
Cancer Sci
; 111(10): 3759-3769, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32716114
18.
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Liver Int
; 40(8): 2008-2020, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32279446
19.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(2): 282-296, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30665869
20.
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Invest New Drugs
; 37(1): 118-126, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29995286